ELVN-002-001 A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients with HER2 Mutant Non-Small Cell Lung Cancer

NCT05650879

A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients with HER2 Mutant Non-Small Cell Lung Cancer

Associated Conditions

Lung Cancer

Principal Investigator

Sponsor

Enliven Therapeutics

The purpose of this study is to test the safety and early signs of efficacy of an experimental drug called ELVN-002 for the treatment of solid tumors carrying HER2 genetic alterations, in particular NSCLC and breast cancer.

This study is currently enrolling.